[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 5, 2005

High-Dose Statins in Acute Coronary Syndromes

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(1):36-39. doi:10.1001/jama.293.1.38-a

To the Editor: Dr Nissen’s editorial1 hypothesizes that the early benefits of statin therapy for patients with ACS is due to the anti-inflammatory effects of these drugs, whereas the delayed benefits are lipid-modulated. He bases this on the differences in high sensitivity C-reactive protein reduction in the MIRACL2 and PROVE IT trials3 (34% and 38%, respectively) and the much smaller reduction in the A to Z trial4 (16.7%), which also had a lack of early outcome benefits in the group receiving 80 mg of simvastatin. However, there were important differences between the trials that may have affected the results. The A to Z trial population was older, the events were more acute, and the high sensitivity C-reactive protein levels were higher at baseline than in the PROVE IT trial. Also, the A to Z trial was conducted internationally (only 20% in the United States) while the PROVE IT trial was conducted entirely in the United States. These differences in the study populations may have accounted for the outcome differences.

First Page Preview View Large
First page PDF preview
First page PDF preview
×